Skip to main content
. 2018 Jul 25;159(8):1580–1591. doi: 10.1097/j.pain.0000000000001246

Figure 8.

Figure 8.

Adenosine signaling modulates pain hypersensitivity behaviors in resiniferatoxin (RTX) neuropathy. This diagram shows an analgesia pathway in small-fiber neuropathy: (left panel) membrane-bound PAP hydrolysis AMP into adenosine (1) which activates A1Rs as the cellular analgesia mechanism (2). (3) TRPV1 coexpressed with PAP and A1Rs, and TRPV1 were depleted by RTX, causes a decrease in analgesic adenosine signaling, including a reduction in PAP ectonucleotidase activity and A1Rs depletion (dotted profiles in right panel). The reduced PAP ectonucleotidase activity causes a decrease in extracellular AMP hydrolysis (4), which results in a reduction in adenosine. (5) A parallel reduction of A1R(+) leads to the disability of adenosine signaling and further exacerbates the development of pain hypersensitivity (6). A1R, adenosine A1 receptor; AMP, adenosine monophosphate; PAP, prostatic acid phosphatase; TRPV1, transient receptor potential vanilloid type 1.